10.12.2023
Beyfortus (Nirsevimab) — a long-acting monoclonal antibody for prevention of severe respiratory syncytial virus (RSV) among infants and children — is now available for providers to order. Nirsevimab may be given in child's 1st year and then their 2nd RSV season for some high-risk patients.
- MHC Facilities: MMC P&T has approved the formulary addition of Nirsevimab for use in MHC pediatric and family medicine clinics, as well as for high-risk NICU discharges during RSV season, using the same inclusion criteria previously used to determine Synagis (Palivizumab) eligibility. This inpatient restriction is consistent with practice at other Michigan health systems. Healthy infants are recommended to receive a dose at their 1st post-discharge pediatrician visit, or 1st visit during RSV season for those born outside of the season.
The CDC does not recommend Nirsevimab for most infants born to a mother who received maternal RSV vaccine, except for infants where <14 days have elapsed between vaccination and birth.
For more on prescribing Nirsevimab, read AAP's Nirsevimab FAQs.